Does the media prefer BMY or RPRX?

In the previous week, Bristol Myers Squibb had 11 more articles in the media than Royalty Pharma. MarketBeat recorded 19 mentions for Bristol Myers Squibb and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.86 beat Bristol Myers Squibb's score of 0.64 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 11 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Royalty Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SNY or RPRX?

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $48.92B 2.06 $8.84B $1.91 21.81 Royalty Pharma $2.54B 13.07 $770.95M $1.45 39.76

Is SNY or RPRX more profitable?

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Royalty Pharma 32.14% 30.01% 14.91%

Does the media prefer SNY or RPRX?

In the previous week, Royalty Pharma had 3 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for Royalty Pharma and 5 mentions for Sanofi. Royalty Pharma's average media sentiment score of 0.86 beat Sanofi's score of 0.60 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, RPRX or GSK?

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Royalty Pharma $2.54B 13.07 $770.95M $1.45 39.76 GSK $43.07B 2.34 $7.54B $3.20 15.55

Is RPRX or GSK more profitable?

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Royalty Pharma 32.14% 30.01% 14.91% GSK 14.56% 43.23% 11.60%

Does the media favor RPRX or GSK?

In the previous week, Royalty Pharma had 2 more articles in the media than GSK. MarketBeat recorded 8 mentions for Royalty Pharma and 6 mentions for GSK. Royalty Pharma's average media sentiment score of 0.86 beat GSK's score of 0.18 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RPRX or TAK?

Royalty Pharma presently has a consensus price target of $61.29, indicating a potential upside of 6.31%. Given Royalty Pharma's higher possible upside, research analysts clearly believe Royalty Pharma is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media favor RPRX or TAK?

In the previous week, Royalty Pharma and Royalty Pharma both had 8 articles in the media. Royalty Pharma's average media sentiment score of 0.86 beat Takeda Pharmaceutical's score of 0.20 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RPRX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 33 more articles in the media than Royalty Pharma. MarketBeat recorded 41 mentions for Teva Pharmaceutical Industries and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.86 beat Teva Pharmaceutical Industries' score of 0.42 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 12 Very Positive mention(s) 6 Positive mention(s) 17 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Royalty Pharma (RPRX) Competitors

$57.65 -0.87 (-1.49%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$57.71 +0.06 (+0.10%)

As of 09:13 AM Eastern

Compare

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

Should you buy Royalty Pharma stock or one of its competitors? Royalty Pharma's main competitors and comparable companies include Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Royalty Pharma compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.1%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Royalty Pharma has increased its dividend for 5 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb currently has a consensus price target of $67.06, indicating a potential upside of 9.67%. Royalty Pharma has a consensus price target of $61.29, indicating a potential upside of 6.31%. Given Bristol Myers Squibb's higher possible upside, equities analysts plainly believe Bristol Myers Squibb is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bristol Myers Squibb has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Royalty Pharma	32.14%	30.01%	14.91%

In the previous week, Bristol Myers Squibb had 11 more articles in the media than Royalty Pharma. MarketBeat recorded 19 mentions for Bristol Myers Squibb and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.86 beat Bristol Myers Squibb's score of 0.64 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	11 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb has higher revenue and earnings than Royalty Pharma. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.59	$7.05B	$4.54	13.47
Royalty Pharma	$2.54B	13.07	$770.95M	$1.45	39.76

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Bristol Myers Squibb beats Royalty Pharma on 12 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to Sanofi?

Sanofi (NASDAQ:SNY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Sanofi has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$48.92B	2.06	$8.84B	$1.91	21.81
Royalty Pharma	$2.54B	13.07	$770.95M	$1.45	39.76

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Royalty Pharma had 3 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for Royalty Pharma and 5 mentions for Sanofi. Royalty Pharma's average media sentiment score of 0.86 beat Sanofi's score of 0.60 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Royalty Pharma	32.14%	30.01%	14.91%

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 5 consecutive years.

Sanofi presently has a consensus target price of $49.50, suggesting a potential upside of 18.82%. Royalty Pharma has a consensus target price of $61.29, suggesting a potential upside of 6.31%. Given Sanofi's higher possible upside, equities research analysts clearly believe Sanofi is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Royalty Pharma beats Sanofi on 14 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to GSK?

Royalty Pharma (NASDAQ:RPRX) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Royalty Pharma presently has a consensus target price of $61.29, suggesting a potential upside of 6.31%. GSK has a consensus target price of $56.50, suggesting a potential upside of 13.56%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
GSK	2 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.09

Royalty Pharma has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.6%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. GSK pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.54B	13.07	$770.95M	$1.45	39.76
GSK	$43.07B	2.34	$7.54B	$3.20	15.55

In the previous week, Royalty Pharma had 2 more articles in the media than GSK. MarketBeat recorded 8 mentions for Royalty Pharma and 6 mentions for GSK. Royalty Pharma's average media sentiment score of 0.86 beat GSK's score of 0.18 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
GSK	14.56%	43.23%	11.60%

Summary

Royalty Pharma beats GSK on 12 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to Takeda Pharmaceutical?

Royalty Pharma (NASDAQ:RPRX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.5%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma has increased its dividend for 5 consecutive years.

Royalty Pharma has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

In the previous week, Royalty Pharma and Royalty Pharma both had 8 articles in the media. Royalty Pharma's average media sentiment score of 0.86 beat Takeda Pharmaceutical's score of 0.20 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma presently has a consensus price target of $61.29, indicating a potential upside of 6.31%. Given Royalty Pharma's higher possible upside, research analysts clearly believe Royalty Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Royalty Pharma has higher earnings, but lower revenue than Takeda Pharmaceutical. Royalty Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.54B	13.07	$770.95M	$1.45	39.76
Takeda Pharmaceutical	$4.62T	0.01	-$1.01B	$0.34	55.40

Royalty Pharma has a net margin of 32.14% compared to Takeda Pharmaceutical's net margin of 3.80%. Royalty Pharma's return on equity of 30.01% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Royalty Pharma beats Takeda Pharmaceutical on 14 of the 18 factors compared between the two stocks.

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Royalty Pharma (NASDAQ:RPRX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Royalty Pharma currently has a consensus target price of $61.29, suggesting a potential upside of 6.31%. Teva Pharmaceutical Industries has a consensus target price of $43.73, suggesting a potential upside of 11.83%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Teva Pharmaceutical Industries has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.54B	13.07	$770.95M	$1.45	39.76
Teva Pharmaceutical Industries	$17.26B	2.64	$1.41B	$0.60	65.17

In the previous week, Teva Pharmaceutical Industries had 33 more articles in the media than Royalty Pharma. MarketBeat recorded 41 mentions for Teva Pharmaceutical Industries and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.86 beat Teva Pharmaceutical Industries' score of 0.42 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	12 Very Positive mention(s)	6 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Royalty Pharma has a net margin of 32.14% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Royalty Pharma has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Summary

Royalty Pharma and Teva Pharmaceutical Industries tied by winning 8 of the 16 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPRX vs. The Competition

Export

Metric	Royalty Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33.65B	$12.61B	$7.31B	$13.28B
Dividend Yield	1.61%	2.63%	2.52%	12.57%
P/E Ratio	39.76	792.28	274.10	25.70
Price / Sales	13.07	857.09	672.61	90.85
Price / Cash	12.25	88.64	77.80	52.76
Price / Book	3.43	10.57	10.48	6.32
Net Income	$770.95M	$2.81B	$3.49B	$359.73M
7 Day Performance	-2.17%	-0.17%	-0.68%	0.17%
1 Month Performance	-6.00%	-1.39%	-3.18%	-3.27%
1 Year Performance	61.17%	2.83%	15.13%	5.58%

Royalty Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPRX Royalty Pharma	3.8919 of 5 stars	$57.65 -1.5%	$61.29 +6.3%	+59.1%	$33.65B	$2.54B	39.76	100
BMY Bristol Myers Squibb	4.7436 of 5 stars	$62.74 -0.5%	$66.72 +6.3%	+36.4%	$128.81B	$48.19B	13.82	32,500	Analyst Forecast
SNY Sanofi	3.7019 of 5 stars	$42.50 +0.0%	$49.50 +16.5%	-11.1%	$102.99B	$49.35B	22.25	74,846
GSK GSK	3.7963 of 5 stars	$51.15 +1.9%	$56.50 +10.5%	+22.9%	$101.58B	$43.07B	15.99	66,841	Dividend Cut
TAK Takeda Pharmaceutical	1.6365 of 5 stars	$18.91 flat	N/A	+25.1%	$60.59B	$28.32B	55.62	47,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPRX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

How does Royalty Pharma compare to Bristol Myers Squibb?

Summary

How does Royalty Pharma compare to Sanofi?

Summary

How does Royalty Pharma compare to GSK?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

How does Royalty Pharma compare to Bristol Myers Squibb?

Is BMY or RPRX a better dividend stock?

Do analysts recommend BMY or RPRX?

Which has more risk & volatility, BMY or RPRX?

Is BMY or RPRX more profitable?

Does the media prefer BMY or RPRX?

Which has preferable earnings and valuation, BMY or RPRX?

Do insiders and institutionals have more ownership in BMY or RPRX?

Summary

How does Royalty Pharma compare to Sanofi?

Which has more risk and volatility, SNY or RPRX?

Which has better earnings & valuation, SNY or RPRX?

Do insiders & institutionals have more ownership in SNY or RPRX?

Does the media prefer SNY or RPRX?

Is SNY or RPRX more profitable?

Is SNY or RPRX a better dividend stock?

Do analysts rate SNY or RPRX?

Summary

How does Royalty Pharma compare to GSK?

Do insiders and institutionals hold more shares of RPRX or GSK?

Do analysts prefer RPRX or GSK?

Which has more risk & volatility, RPRX or GSK?

Is RPRX or GSK a better dividend stock?

Which has better earnings and valuation, RPRX or GSK?

Does the media favor RPRX or GSK?

Is RPRX or GSK more profitable?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Is RPRX or TAK a better dividend stock?

Which has more volatility and risk, RPRX or TAK?

Does the media favor RPRX or TAK?

Do analysts recommend RPRX or TAK?

Which has better valuation & earnings, RPRX or TAK?

Is RPRX or TAK more profitable?

Do insiders & institutionals have more ownership in RPRX or TAK?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Do insiders and institutionals hold more shares of RPRX or TEVA?

Do analysts recommend RPRX or TEVA?

Which has better earnings & valuation, RPRX or TEVA?

Does the media favor RPRX or TEVA?

Is RPRX or TEVA more profitable?

Which has more volatility and risk, RPRX or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools